1/ This is unreal. The study title is "Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial." It is being cited as evidence that rapid antigen tests can make social events safe. But there are a couple problems...
2/ They gave rapid tests to over 1000 people and randomly divided those who tested negative into two groups. One went to a concert, where they were encouraged to dance and sing, and the others stayed home. I encourage you to read the entire abstract in the 2 pictures below.
3/ Results: None who went to the concert tested positive for Covid eight days later, but two of those who stayed home tested positive. Yay for rapid tests, right? Not exactly.
4/ You see, when they screened study participants with rapid antigen tests before the concert, NONE tested positive. That is to say, the rapid tests had ZERO effect on the results here.
5/ One would think this would merit a mention in the abstract, but the study authors apparently didn't think so. The study title indicates it's an RCT of rapid test screening for an indoor concert, yet there's no mention in the abstract that the rapid tests were irrelevant.
6/ Perhaps even more astonishing, nowhere in the discussion section of the paper do they mention that none of the rapid antigen tests were positive and that therefore no one was screened out of participating in the concert. Instead, they sing the praises of rapid tests.
7/ The authors do not let a little thing like the total irrelevance of the rapid antigen tests to the study's results prevent them from concluding their study provides evidence of the effectiveness of rapid tests as screening tools for indoor social events. You can't make it up.
8/ Though not mentioned in the study abstract, we are eventually told that concert attendees were required to wear an N95 mask at all times, except when drinking. I'm 100% for wearing N95 masks, but this is not likely to ever be adapted as policy in the real world.
9/ The ventilation was also extraordinarily good at the concert, maintaining CO2 at or below 800 ppm, much lower than the typical school classroom.
10/ In other words, the study was designed to give a result indicating the effectiveness of rapid antigen tests, & despite its failure to provide that result, the authors manage to come to the conclusion they wanted anyway.
11/ I should add that I'm open to the possibility that rapid antigen tests could be effective in preventing Covid transmission. But this study is a joke. It's disturbing that it was published by the Lancet & is apparently being taken seriously by prominent experts.
Addendum/ This study was funded by the events company Primavera Sound Group and YoMeCorono, which I know nothing about, but which appears to be funded by dozens of (mostly) Spanish corporations. yomecorono.com/en/empresas-qu…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Very proud to be a co-author on this comprehensive preprint on the novel, growing saltation lineage BA.3.2, together with @Tuliodna, Darren Martin, Dikeledi Kekana, and lead author @graemedor. 1/9
I would normally write a summary 🧵 of the BA.3.2 mutational analysis here, but as much of my contribution parallels my previous BA.3.2 threads I'll just link to those here, w/brief descriptions of each.
BA.3.2 emerged in Nov 2024 after ~3 years of intrahost evolution with >50 new spike AA muts, but since then, it's changed very little. Could the drug molnupiravir (MOV) galvanize BA.3.2 into pursuing new evolutionary paths? A new 89-mut MOV BA.3.2 seq suggests it could. 1/11
Background on MOV: It's a mutagenic drug. Its purpose is to cause so many mutations that the virus becomes unviable & is cleared. But we've long known this often does not happen. Instead, the virus persists in highly mutated form & can be transmitted. 2/
I was an author on a paper published in @Nature that conclusively showed not only that MOV has created highly mutated, persistent viruses, but that these viruses have transmitted numerous times. See 🧵 below by lead author @theosanderson. 3/
The most valuable viral research tools—@nextstrain & CovSpectrum—are being destroyed, not only blocked from new data but now forbidden from even sharing info from the PAST. Why?
Because GISAID is run dictatorially by a con man, paranoid egomaniac, & liar named Peter Bogner. 1/
I use CovSpectrum & Nextstrain every day—& I'm not the only one. Every Covid thread I've ever posted here has relied partly on CovSpectrum & Nextstrain for information & visuals. These vital tools have now been stolen from us by a world-class grifter. 2/ thinkglobalhealth.org/article/to-fin…
For years scientists knew something was very, very wrong with GISAID, but the breakout story (from which much of this 🧵is based) came 2 years ago in @ScienceMagazine from @sciencecohen & Martin Enserik. 3/ science.org/content/articl…
3/77 sequences from the latest Netherlands upload are BA.3.2 as well as 4/86 seqs from Queensland, Australia, consistent w/the steady, slow growth we've seen in Germany, the UK, Ireland, & much of Australia. 1/4
One interesting (and possibly coincidental) aspect of the BA.3.2 tree: Two large branches have NSP14 mutations at adjacent AA residues—ORF1b:T1896I and ORF1b:H1897Y. 2/4
I don't have any idea what functional effects either of these mutations would have. They are both C->T mutations, which is the most common type, but they've been relatively uncommon throughout the pandemic, with fewer than 8000 sequences combined. 3/4
The first instance involved a small cluster of sequences that hospitalized several people & resulted in the death of a young child in early 2022. More on this one later. 2/15
The most recent example requires some background. In late 2024, a spectacularly mutated Delta appeared in Spain with 40 new spike mutations and numerous Cryptic markers.
Normally, I would write a thread about such a remarkable sequence, but there were some issues... 3/15
@StuartTurville has pointed out that WA delayed Covid spread longer than elsewhere in Australia. China has a somewhat similar immune history (as do other SE Asian countries). Perhaps BA.3.2 will do well in China once it arrives there? 2/4